(Q28265163)

English

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

scientific article

In more languages

Statements

scholarly article

0 references

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment (English)

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

object named as

Nusrat Husain

3

0 references

object named as

Bill Deakin

9

0 references

Jaime Eduardo Cecilio Hallak

2

object named as

Jaime Hallak

0 references

author name string

Imran B Chaudhry

1

0 references

Fareed Minhas

4

0 references

John Stirling

5

0 references

Paul Richardson

6

0 references

Serdar Dursun

7

0 references

Graham Dunn

8

0 references

language of work or name

0 references

publication date

September 2012

0 references

Journal of Psychopharmacology

0 references

26

0 references

9

0 references

1185-93

0 references

Association of schizophrenia and autoimmune diseases: linkage of Danish national registers

1 reference

https://api.crossref.org/works/10.1177/0269881112444941

20 April 2017

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1177/0269881112444941

20 April 2017

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

1 reference

https://api.crossref.org/works/10.1177/0269881112444941

20 April 2017

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Brain volume changes in the first year of illness and 5-year outcome of schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Amoxapine as an antipsychotic: comparative study versus haloperidol

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Neuroprotection by tetracyclines

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an inflammatory process?

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Schizophrenia: new pathological insights and therapies

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

A separate disease within the syndrome of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Minocycline treatment in acute stroke: an open-label, evaluator-blinded study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Antipsychotic drug effects on brain morphology in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Minocycline as adjunctive therapy for schizophrenia: an open-label study

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Glutamate receptor dysfunction and schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison.

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

The NADPH oxidase NOX2 controls glutamate release: a novel mechanism involved in psychosis-like ketamine responses

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine.

1 reference

https://api.crossref.org/works/10.1177%2F0269881112444941

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28265163&oldid=1970720688"